Navigation Links
Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Date:3/16/2009

- Conference Call Today at 4:30 p.m. Eastern Time -

SAN FRANCISCO, March 16 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the fourth quarter and year ended December 31, 2008.

"We had a very productive 2008 and are looking forward to an equally exciting 2009. We have made excellent progress across our pipeline and are on track to be in Phase 3 testing in all of our programs in 2009 -- Dimebon in both Alzheimer's and Huntington's diseases and MDV3100 for castration-resistant prostate cancer," said David Hung, M.D., president and chief executive officer of Medivation. "We and Pfizer are jointly executing a comprehensive Phase 3 development program for Dimebon in Alzheimer's disease and are already well on our way with the ongoing CONNECTION study, the recent initiation of a large safety trial designed to support a potential earlier NDA filing date, and the soon-to-be-initiated CONCERT study of Dimebon in combination with Aricept. In addition, with Pfizer, we had a successful end-of-Phase 2 meeting with the FDA for Dimebon in Huntington's disease."

Corporate Update

Dimebon

Alzheimer's Disease:

  • On track with patient enrollment in CONNECTION, a confirmatory Phase 3 trial in mild-to-moderate patients, allowing for expected completion of enrollment in 2009. We have 66 open sites in the U.S., Europe and South America.
  • Initiated a placebo-controlled Phase 3 safety study in 750 Alzheimer's disease patients on a variety of background antidementia drugs. The purpose of the safety study is to generate a sufficient safety database to give us the option for an earlier-than-planned filing of our initial marketing application should
    '/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
2. Medivation Presents New Data on Dimebons Novel Mechanism of Action
3. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
4. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
5. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
6. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
7. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
8. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
9. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
10. Medivation Announces Participation in Upcoming Conferences
11. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer and ... production capability to serve biotechnology pharmaceutical clients. A ... continues to drive Nitto Avecia to enhance synthesis ... , In Fall 2014, Nitto Avecia first ... its Milford, MA facility, which is recognized as ...
(Date:4/30/2015)...  Pfenex Inc. (NYSE MKT: PFNX) a clinical-stage ... therapeutics including high value and difficult to manufacture ... announced underwritten public offering of 6,750,000 shares of ... of $15.50 per share. This includes the exercise ... to purchase up to 750,000 additional shares of ...
(Date:4/30/2015)... Available in select spas in the ... Phytomer’s DOUCEUR INTEMPORELLE Restorative Shield Cream provides immediate ... the weakening threat of inflammaging, aging directly caused ... star ingredient GLYCOSEA, a complex of restructuring plankton ... soothing minerals and trace elements. GLYCOSEA works to ...
(Date:4/29/2015)... (PRWEB) April 29, 2015 SPIE ... and imaging on the East Coast, reaffirmed its value ... researchers, applications developers, and industry suppliers to meet and ... for multiple applications. , The event included 55 conferences ... and scientific sensing and imaging -- and an exhibition ...
Breaking Biology Technology:Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3SPIE DSS provides venue for collaboration vital to research, applications advances 2SPIE DSS provides venue for collaboration vital to research, applications advances 3SPIE DSS provides venue for collaboration vital to research, applications advances 4
... North Carolina Sen. John Edwards polled well in last weeks ... Free Trade Agreement has been a raw deal. It was ... to blame the states economic troubles on those dastardly Canadians ... Free trade is a part of saving Wisconsin, not ruining ...
... Wis.- Gundersen Lutheran Health System is reducing surgery delays ... management of its surgical instruments and trays by using ... Minn.- based Lawson Software. , ,Gundersen Lutheran operates ... of the nation's largest group medical practices, community clinics, ...
... Muskego, Wis - The City of Muskego, Wis., has ... intranet site and their public Web site . ... Software , an Australian software company specializing in knowledge ... government. , ,Prior to choosing ISYS, the City evaluated ...
Cached Biology Technology:A Vote Against Free Trade is a Vote Against Wisconsins Long-Term Interests 2Gunderson Lutheran Implements Instrument Management Systems 2
(Date:4/2/2015)... Sweden , April 2, 2015 ... its touch fingerprint sensor FPC1025 from the distributor World ... will commence during Q2 2015 although the major part ... The sensors will be used by smartphone manufacturers in ... 110 MSEK is included in the communicated revenue guidance ...
(Date:4/1/2015)... April 1, 2015   Medisafe ™, the leading ... across iOS and Android smartphones ... biofeedback into the platform to allow patients to track ... the first time, patients will be able to visualize ... impacts important biometrics, such as glucose levels and blood ...
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... and Harvard Medical School, has been awarded a Grand ... as part of the federal stimulus package, to pursue ... for rapid DNA sequencing to better understand autism,s causes. ... stimulus package, officially starts September 30. All genetic sequence ...
... FAIRFAX, Va.The Society of Interventional Radiology presents ... five-day course featuring top interventional radiologists, neurointerventionists, ... to gain and/or upgrade skills to incorporate ... The course incorporates lectures, panel ...
... of biodiversity loss is worsening in many places, some ... 13-16 for the DIVERSITAS Open Science Conference. Experts ... continued to accelerate. Since 1992, the most conservative estimates ... of California has been converted mostly for food and ...
Cached Biology News:Stimulus grant to fund whole-genome sequencing in children with autism 2Stimulus grant to fund whole-genome sequencing in children with autism 3Top interventional radiologists, neurointerventionists explore stroke care through CLOTS 2
...
Mouse monoclonal antibody raised against a partial recombinant FBXO11. NCBI Entrez Gene ID = FBXO11...
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
Mouse polyclonal antibody raised against a partial recombinant LASS3. NCBI Entrez Gene ID = 204219...
Biology Products: